WOBURN, Mass.–BioTrove, Inc. today announced the launch of its RapidFire® 300 system for high-throughput screening of in vitro ADME assays. Producing label-free data at six to eight seconds per sample, drug discovery researchers can now use the high-throughput, mass spectrometry based method to analyze in vitro ADME assays in a fraction of the time required for conventional HPLC mass spectrometry techniques.

The RapidFire 300 expands the in vitro ADME applications of the platform beyond drug-drug interaction (DDI) screening. DDI was first launched two years ago on the RapidFire 200 system and is used by numerous pharmaceutical and biotechnology companies to provide high quality DDI data at record throughput. This latest addition to the RapidFire screening tool kit will be introduced at the American Society for Mass Spectrometry’s (ASMS) 57th Annual Conference in Philadelphia, Pennsylvania, May 31-June 4.

As the newest addition to the RapidFire instrumentation portfolio, the RapidFire 300 system enables researchers to perform a wide range of in vitro ADME assays with 24-hour, unattended operation. The RapidFire-MS system streamlines drug discovery workflow, significantly decreasing the processing time compared to conventional MS-based technologies and helps to eliminate bottlenecks in drug discovery while providing accurate results for data-driven decision making. RapidFire 300 can fully integrate with any manufacturer’s triple quadrupole mass spectrometer and provide data compatible with customers’ existing laboratory information management systems.

“ADME data is critical in all phases of a fully integrated drug development program but data in the lead discovery stage was previously limited by time and labor intensive screening platforms,” said Can “Jon” Özbal, Ph.D., Vice President and General Manager, BioTrove RapidFire Business Unit. “RapidFire 300 was developed to meet investigators’ demand for high quality in vitro ADME data with a short turnaround time.” The RapidFire 300 system can be used for a variety of in vitro ADME applications, including: CYP Inhibition

Metabolic Stability

P-Glycoprotein Inhibition

Plasma Protein Binding

Permeability Assays – Caco, PAMPA

CYP Induction

Scientists from Boehringer Ingelheim, Merck and Johnson & Johnson will speak about advancing drug discovery and their experience with the RapidFire system on June 2, at 6:30 p.m., in BioTrove’s ASMS hospitality suite (Marriott Hotel, Suite J). BioTrove researchers and customers will also present talks and posters at the conference on the RapidFire system as follows: Monday, June 1

Oral Session – Chromatography-Mass Spectrometry Approaches to Increase Throughput in Discovery PK Assays, Ballroom B (10:10 a.m.)

A Novel and Integrated Platform for Fully Automated High-Throughput LCMSMS Analysis of in vitro ADME Samples; A. Luippold, T. Arnhold, W. Joerg, K. Klinder, K. Schumacher; Boehringer Ingelheim Pharma GmbH & Co KG.

Oral Session – Tandem MS of Whole Proteins and Protein Complexes, Room 201 (3:10 p.m.)

High Throughput Quantitative Screening Measuring Intact Proteins by a Novel Rapid Mass Spectrometric Approach; K. Alving, G. Asmussen, T. Gladysheva, J. Lillie, A. Cohen, B. Wang; Genzyme Corporation.

Poster Sessions – Drug Metabolism: High Throughput, Exhibit Hall AB (10:30 a.m. – 2:30 p.m.)

P 437: Application of the BioTrove RapidFire® Ultra-fast Online SPE-MS/MS System for Compound-specific Analysis of in-vitro ADME Samples; A. Paiva, A. Wagner, X. Cai, Y. Li, J. Kolb, J. Herbst, C. Conway, H. Weller, W. Shou; Bristol-Myers Squibb.

P 438: Evaluation of accurate mass TOF-MS for use in high throughput CYP450 inhibition screening; W. LaMarr, M. Romm, N. Parikh, L. Frick, C. Özbal; BioTrove, Inc.

Thursday, June 4

Poster Sessions – High Throughput Analysis/Robotics, Exhibit Hall AB (10:30 a.m. – 2:30 p.m.)

P 669:

Label Free High-Throughput Whole Protein Kinase Screening Assay; M. Romm, N. Parikh, T. Stanley, J. Williams, W. Lamarr, C. Özbal; BioTrove, Inc., GlaxoSmithKline.

P 677:

Discovery of Novel Inhibitors of Serine Palmitoyltransferase (SPT) by Mass Spectrometry-Based High-Throughput Screening (HTS); P. Meyn, P. Maresca, W. Lamarr, P. Rye, M. Brooks, A. Babbs, M. Procter, D. Pan, C. Özbal, A. Garton; OSI Pharmaceuticals, BioTrove, Inc., Prosidion Limited.

BioTrove representatives will be available throughout the conference to discuss RapidFire solutions at Booth #66 during the day and in Hospitality Suite J at the Marriott Hotel on June 1-3, 6:30-11:00 p.m. More information on BioTrove, its RapidFire capabilities and the Company’s presence at ASMS is available at www.BioTrove.com. About BioTrove, Inc.

BioTrove, Inc. offers two innovative technology platforms: OpenArray®, which advances genomic research in a wide range of life science fields, including agriculture, disease research, and public health, and RapidFire®, which enables the acceleration of drug discovery and pipeline decisions. With 11 of the top 12 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals. The OpenArray® Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics. Life Technologies globally markets the OpenArray SNP genotyping platform under the TaqMan® OpenArray® SNP Genotyping brand. BioTrove is a licensee of Life Technologies global patent rights related to the real-time thermal cyclers, microfluidics and data analysis. RapidFire® Mass Spectrometry (RF-MS) feeds samples directly to the mass spectrometer at six to eight seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RF-MS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, ADME assays and directed evolution studies.